Molbio Diagnostics Limited witnessed a significant shareholding change as India Business Excellence Fund III disposed of 23,77,627 equity shares on September 30, 2026. This transaction represents a 2.06% reduction in the fund's total holding, executed through the open market.

The disposal triggered a disclosure requirement under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing was submitted to both BSE and NSE by the fund's investment manager, MO Alternate Investment Advisors Private Limited.

Shareholding movement

Prior to this transaction, India Business Excellence Fund III held 1,02,76,750 shares, constituting 8.92% of the company's total voting capital. The sale of 23,77,627 shares has reduced the fund's stake to 78,99,123 shares, or 6.85% of the total diluted share capital.

Regulatory compliance and details

The disclosure confirms that the seller does not belong to the promoter or promoter group category. The transaction involved only equity shares carrying voting rights, with no involvement of warrants, convertible securities, or encumbered shares. The total equity share capital of Molbio Diagnostics remained unchanged at 11,52,39,996 equity shares of face value ₹1 each.

What the numbers show

The data reveals a concentrated exit strategy by a non-promoter institutional investor. By selling exactly enough shares to breach the 2% threshold in a single day, the fund reduced its exposure by nearly one-quarter of its previous position (from 8.92% to 6.85%). This significant drop in institutional backing may signal a shift in the fund's portfolio allocation or a reassessment of the company's near-term outlook, although no specific reasons for the sale were provided in the regulatory filing.

Molbio Diagnostics shares worth ₹305.42 crore were flagged by a real-time trade-scanning system after approximately 22,32,574 shares changed hands on BSE at a price of ₹1,315.00 per share.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Large-trade signal details

The following details were captured from the flagged activity:

The signal reflects a cluster of trades in Molbio Diagnostics shares printed within a short window at or near ₹1,315.00, flagged for size and speed by the scanning system. No buyer, seller, broker, or client identity is known at this stage, as such disclosures are made only by the exchange after market close.

What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.